The endotest, a worldwide innovation to screen for endometriosis
How long does it take to detect endometriosis? How urgent is the diagnosis of endometriosis?
Endometriosis Endometriosis is a disease that affects 1 in 10 women. In addition to being a very painful and disabling disease, the medical uncertainty surrounding this disease means that it takes an average of 8 to 12 years between the appearance of the first symptoms and the diagnosis of endometriosis. It is a disease that is little known by primary care health professionals. There are as many endometrioses as there are menstruating women. The disease is multifactorial and polymorphic (the symptoms differ from one person to another), which makes it very difficult to diagnose.
Another major problem: the methods available today (i.e. clinical examinations, imaging and biological samples) do not give a definite diagnosis. Some forms of endometriosis can be detected, but not all.
Today, laparoscopy is the reference examination for endometriosis. But the problem is that it is an invasive examination, which must be performed under general anesthesia.
To learn about the definition of endometriosis, the causes and the diagnosis, read our blog post here.
The challenge in recent years has been to develop a non-invasive test. To do this, a French company has come up with a major innovation that will revolutionize the detection of the disease, hundreds of potential biomarkers have been analyzed.
The endotest, a diagnosis that eliminates any delay in the diagnosis of endometriosis?
It was in January 2021 that a team of doctors who are experts in endometriosis associated with artificial intelligence engineers (from the start-up Ziwig) launched the Endo-miRNA clinical trial. The test is based on the simultaneous acquisition of data relating to millions of DNA or RNA fragments that will be analyzed by artificial intelligence to identify a powerful and reliable endometriosis signature.
With the Endo-miRNA clinical trial, researchers were able to distinguish between patients with endometriosis and those without.
This led to a worldwide innovation: the Ziwig Endotest saliva test.
This is a revolution and a huge advance in the management of endometriosis: the saliva test will reduce the average diagnosis time from 8 years to just a few days. The number of medical errors will be limited, the diagnosis will allow early treatment of endometriosis and it will slow down or even stop the worsening of pain and other symptoms, and therefore improve the quality of life of patients.
But that's not all: the Ziwig Endotest will help avoid unnecessary surgical procedures (such as diagnostic laparoscopy) that patients with symptoms close to the disease but without the disease were facing.
Overall, in the long term, the medical and social costs of the disease should be reduced. With the arrival of this test on the market, patients living in medical deserts will be able to benefit from a reliable and early diagnosis.
In addition, the test is very simple to use, as women take the saliva sample themselves at home using a self-sampling kit. Then, they just have to send the kit back to the laboratory, which will confirm or not the diagnosis of endometriosis. This test has an accuracy close to 100%.
This innovation is a huge step forward for all women with endometriosis. It is a considerable and major advance for women's health.
By buying our menstrual panties, you contribute to research for endometriosis since 10% of our profits are donated to research associations for this disease.
Source : Endomind
C’est une innovation inespérée pour les malades non diagnostiquées, quelle avance inattendue !
Une grande avancée qui va changer la vie de beaucoup de femme. C’est super.
wow, très impressionnant! Je suis particulièrement intrigué par le fait que cette technologie innovante repose sur le croisement de l’intelligence artificielle et du séquençage à haut débit. Un bel exemple de recherche interdisciplinaire. Cela aura un impact énorme sur le bien-être de nombreuses femmes.
Oui c’est une nouvelle encourageante pour les femmes souffrant de cette maladie mais il ne faut pas susciter trop vite d’espoirs insensés. Un biomarqueur c’est comme un médicament, nécessitant donc des études cliniques à grande échelle, de confirmations et de définition du service médical rendu. Un test doit aussi s’inscrire dans une stratégie en tenant compte du contexte. Une spécificité de 98 % (si elle est confirmée) peut malgré tout générer beaucoup plus de faux positifs que de diagnostics justes si le test est utilisée dans une population à faible prévalence de la maladie. Dans l’étude publiée la prévalence de la maladie était élevée. A suivre donc..
Quelle avancée impressionnante !
Leave a comment